TNF-α-induced up-regulation of pro-inflammatory cytokines is reduced by phosphatidylcholine in intestinal epithelial cells by Treede, Irina et al.
BioMed  Central
Page 1 of 11
(page number not for citation purposes)
BMC Gastroenterology
Open Access Research article
TNF-α-induced up-regulation of pro-inflammatory cytokines is 
reduced by phosphatidylcholine in intestinal epithelial cells
Irina Treede1, Annika Braun1, Petia Jeliaskova1, Thomas Giese2, 
Joachim Füllekrug1, Gareth Griffiths3, Wolfgang Stremmel1 and 
Robert Ehehalt*1
Address: 1Department of Gastroenterology, University of Heidelberg, INF 345, 69120 Heidelberg, Germany, 2Institute of Immunology, University 
of Heidelberg, INF 305, 69120 Heidelberg, Germany and 3Cell Biology Program, EMBL, Postfach 102209, 69117 Heidelberg, Germany
Email: Irina Treede - irina_treede@med.uni-heidelberg.de; Annika Braun - annika_braun@med.uni-heidelberg.de; 
Petia Jeliaskova - petia.j@web.de; Thomas Giese - thomas.giese@urz.uni-heidelberg.de; Joachim Füllekrug - joachim.fuellekrug@med.uni-
heidelberg.de; Gareth Griffiths - griffith@embl-heidelberg.de; Wolfgang Stremmel - wolfgang_stremmel@med.uni-heidelberg.de; 
Robert Ehehalt* - robert_ehehalt@med.uni-heidelberg.de
* Corresponding author    
Abstract
Background: Phosphatidylcholine (PC) is a major lipid of the gastrointestinal mucus layer. We recently showed
that mucus from patients suffering from ulcerative colitis has low levels of PC. Clinical studies reveal that the
therapeutic addition of PC to the colonic mucus using slow release preparations is beneficial. The positive role of
PC in this disease is still unclear; however, we have recently shown that PC has an intrinsic anti-inflammatory
property. It could be demonstrated that the exogenous application of PC inhibits membrane-dependent actin
assembly and TNF-α-induced nuclear NF-κB activation. We investigate here in more detail the hypothesis that
the exogenous application of PC has anti-inflammatory properties.
Methods: PC species with different fatty acid side chains were applied to differentiated and non-differentiated
Caco-2 cells treated with TNF-α to induce a pro-inflammatory response. We analysed TNF-α-induced NF-κB-
activation via the transient expression of a NF-κB-luciferase reporter system. Pro-inflammatory gene
transcription was detected with the help of a quantitative real time (RT)-PCR analysis. We assessed the binding
of TNF-α to its receptor by FACS and analysed lipid rafts by isolating detergent resistant membranes (DRMs).
Results: The exogenous addition of all PC species tested significantly inhibited TNF-α-induced pro-inflammatory
signalling. The expression levels of IL-8, ICAM-1, IP-10, MCP-1, TNF-α and MMP-1 were significantly reduced
after PC pre-treatment for at least two hours. The effect was comparable to the inhibition of NF-kB by the NF-
kB inhibitor SN 50 and was not due to a reduced binding of TNF-α to its receptor or a decreased surface
expression of TNF-α receptors. PC was also effective when applied to the apical side of polarised Caco-2 cultures
if cells were stimulated from the basolateral side. PC treatment changed the compartmentation of the TNF-α-
receptors 1 and 2 to DRMs.
Conclusion: PC induces a prolonged inhibition of TNF-α-induced pro-inflammatory signalling. This inhibition
may be caused by a shift of the TNF-α receptors at the surface to lipid rafts. Our results may offer a potential
molecular explanation for the positive role of PC seen in clinical studies for the treatment of ulcerative colitis.
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Background
Inflammatory bowel disease (IBD) is the result of a
chronic intestinal inflammatory response. While the exact
pathogenesis of IBD remains incompletely understood, it
is likely that the initiation of the immune response is trig-
gered by luminal factors [1]. The nature of these initiating
agents is unclear, but both orally ingested nutrients and
microbial agents have been implicated [2]. It is widely
believed that an impaired barrier function, and in partic-
ular a defect of the mucus layer, leads to an increased
exposure of the mucosal immune system to luminal anti-
gens. In genetically susceptible individuals, this results in
an inappropriate and unrestrained inflammatory
response [3,4].
We have recently shown that both PC and lysophosphati-
dylcholine (LPC) but neither phosphatidylethanolamine
(PE) nor sphingomyelin (SM) are decreased in the mucus
of patients with ulcerative colitis (UC) and that the oral
substitution of PC using slow release preparations is ben-
eficial [5-7]. How luminal PC influences the clinical
course of UC is not yet known, but two scenarios are pos-
sible. First, because of its hydrophobic property, PC coats
the mucus layer, thereby preventing the contact of lumi-
nal bacteria to the mucosa [5,8,9]. With respect to this,
luminal PC has been shown to synergize with conjugated
primary bile salts in the binding of luminal endotoxin,
which in turn leads to a suppressed inflammation beyond
the mucosal surface [10]. On the other hand, we could
recently demonstrate that PC per se has anti-inflamma-
tory properties. PC has been shown to inhibit membrane-
dependent actin assembly and TNF-α-induced MAPkinase
and NF-κB activation [11]. In light of these results, we
hypothesized that luminal PC might be integrated into
the plasma membranes of enterocytes and in turn modu-
late the signalling state of the mucosa in the human intes-
tine. This assumption is further substantiated by studies
using an in vitro phagosome system [12,13] which show
that exogenous PC is indeed involved in the networks
which inhibit pro-inflammatory signalling in mem-
branes.
IBD encompasses two chronic intestinal diseases, Crohn's
disease (CD) and UC, which differ in their microscopic
and macroscopic features although their symptoms are
similar [14]. Ulcerative lesions in IBD are accompanied by
a prominent infiltrate of inflammatory cells including T
lymphocytes, macrophages, neutrophils, and mast and
plasma cells [15]. Mechanisms involved in the recruiting
and activating of these inflammatory cells are thought to
encompass a complex interplay of inflammatory media-
tors. This is reflected by the elevation of various chemok-
ines in the serum and mucosa of IBD patients (for review
see [16]). Over 40 human chemokines are now acknowl-
edged, each with its own specific pattern of cellular chem-
otaxis. The chemokine family is categorised into four
groups depending on the spacing of their first two cysteine
residues [17]. Cumulative studies demonstrate that all
four types of chemokines are involved in the development
of IBD [16]. The expression level of pro-inflammatory
chemokines differed significantly between IBD patients
and controls. Up-regulated chemokine expression in
human biopsies correlated with increasing activity of the
disease [16]. Pro-inflammatory cytokines such as TNF-α
and interleukin 1β (IL-1β) up-regulate the transcription of
chemokine genes and hence the synthesis of chemokines
themselves through the activation of NF-κB [18,19]. As
TNF-α has been shown to be an important player in the
inflammatory process of IBD [20], we previously estab-
lished a model cell system with human intestinal epithe-
lial cells (Caco-2) which we stimulated with TNF-α to
induce a pro-inflammatory response [11]. Using this sys-
tem, we now analysed the effect of various PC species on
the transcriptional levels of selected marker genes. After
PC treatment, the TNF-α induced up-regulation was sig-
nificantly reduced in a time- and dose-dependent manner
depending on the fatty acid composition. PC was effective
when applied to the apical side of polarized Caco-2 cells
if they were stimulated from the basal side. We could
show that the TNF-α effect was dependent on NF-κB activ-
ity and not due to inhibition of the binding of TNF-α to
its receptor. PC treatment changed the compartmentation
of TNF-α-R1 and TNF-α-R2 to lipid rafts, which is a possi-
ble mechanism of action.
Methods
Lipids and reagents
TNF-α was obtained from Promega (Mannheim, Ger-
many) and dissolved in endotoxin-free water containing
1% BSA from Sigma (Deisenhofen, Germany). Aliquots of
10 μg/ml were stored at -70°C. The NF-κB inhibitor SN 50
was from Calbiochem (San Diego, USA). PC 18:2/18:2
(1,2-dilinoleoyl-glycero-3-PC), PC 16:0/16:0 (1,2-
dipalmitoyl-glycero-3-PC), PC 16:0/18:2 (1-palmitoyl-2-
linoleoyl-glycero-3-PC), LPC 16:0 (1-palmitoyl-glycero-3-
PC), PE 16:1/16:1 (1,2-dioleyl-glycerol-3-PE) were from
Sigma (Deisenhofen).
Cells and bacteria
Caco-2w cells are a sub-clone of the human Caco-2BBe
and were selected because of their well-differentiated phe-
notype. They were provided by J. R. Turner (University of
Chicago). Cells were grown at 37°C and 5% CO2 in Dul-
becco's modified Eagle's medium (DMEM) supplemented
with 10% heat-inactivated fetal calf serum, 1% non-essen-
tial amino acid, and antibiotics (55 IU/mL penicillin and
55 μg/mL streptomycin). Vero cells (American Type Cul-
ture Collection; ATCC) were propagated in Dulbecco's
Modified Eagle's Medium (DMEM) supplemented with
5% fetal bovine serum and antibiotics (55 IU/mL penicil-
lin and 55 μg/mL streptomycin). For full polarization cells
were grown for 14 d on 2.5 cm, 0.4 μm pore size TranswellBMC Gastroenterology 2009, 9:53 http://www.biomedcentral.com/1471-230X/9/53
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polycarbonate filters (Costar, Cambridge, USA) as previ-
ously described [21].
Gene expression analyses by RT-PCR quantification
Caco-2 cells were grown under standard conditions in 6-
wells for 48 h to 90% confluence and washed in Dul-
becco's modified Eagle's medium without serum. Then
they were incubated with 10 ng/mL recombinant human
TNF-α (RnD Systems, Wiesbaden-Nordenstadt, Ger-
many) and different PC species for various times at 37°C.
Approximately 1 × 106 cells were collected in 300 μl lysis
buffer from the MagnaPure mRNA Isolation Kit I (RAS,
Mannheim, Germany) and mRNA was isolated with the
MagnaPure-LC device using the mRNA-I standard proto-
col. RNA was reverse transcribed using AMV-RT and oligo-
(dT) as the primer (First Strand cDNA synthesis kit, RAS),
according to the manufacturer's protocol, in a thermocy-
cler. Primer sets specific for the sequences of the selected
genes optimised for the LightCycler (RAS) were developed
and provided by SEARCH-LC GmbH, Heidelberg http://
www.search-lc.com. The PCR was performed with the
LightCycler FastStart DNA Sybr GreenI kit (RAS) accord-
ing to the protocol provided in the parameter specific kits.
To control for the specificity of the amplification prod-
ucts, a melting curve analysis was performed. No amplifi-
cation of unspecific products was observed. The copy
number was calculated from a standard curve obtained by
plotting known input concentrations of four different
plasmids at log dilutions to the PCR cycle number at
which the detected fluorescence intensity reaches a fixed
value. This was done to reduce variations due to handling
errors over several logarithmic dilution steps. To correct
for differences in the content of mRNA, the calculated
copy numbers were normalised according to the average
expression of two housekeeping genes (Cyclophilin B and
β-Actin). Values were thus given as input adjusted to the
copy number per μl of cDNA.
Transient transfection and reporter assays
Caco-2 cells were seeded in 12-wells, grown to a >95%
confluency and transiently transfected with a NF-κB-
dependent luciferase reporter plasmid according to the
manufacturer's instructions (Stratagene, La Jolla, USA).
Cells were then co-treated in medium with or without
TNF-α (10 ng/ml) and with a 200 μM solution of different
PCs for 4 h at 37°C 20 h after transfection. In pre-treat-
ment experiments, cells were first incubated for 10 min-
utes with 200 μmol PC, washed, and afterwards
stimulated with TNF-α (10 ng/ml) only. Luciferase activ-
ity was assayed using the Luciferase Assay Kit (Stratagene)
according to the manufacturer's directions and detected
with a Fluorostar Optima (BMG Labtech, Offenburg, Ger-
many). Each transfection was performed in triplicate and
repeated at least three times.
Flow Cytometry
A 25 μl volume of washed cells (60% density, 2*105 cells),
either pre-treated with a 200 μmol PC or left untreated,
was incubated with 10 μl of biotinylated TNF-α (10 ng/
mL) for 60 min at 4°C. Biotinylated soybean trypsin
inhibitor was used as negative control. A 10 μl volume of
avidin-FITC reagent was then added to each tube and
incubated for an additional 30 min at 4°C in the dark. The
cells were washed twice with 2 ml of 1× RDF1 buffer to
remove unbound avidin-fluorescein and resuspended in
600 μl of 1× RDF1 buffer. The sample was then subjected
to flow cytometric analysis by using 488 nm wavelength
laser excitation (Beckman Coulter). As a test of specificity,
TNF-α biotin was neutralized with an anti-TNF-α anti-
body and then added to the cells to block nonspecific and
specific binding of TNF-α biotin.
Preparation of DRMs
Detergent extraction with Triton X-100 was performed as
described [22]. Cells were grown in 3.5 cm dishes, trans-
fected with TNF-α-R1 and TNF-α-R2 (provided by J. R.
Turner, University of Chicago) and 10–12 h later washed
once with PBS and scraped on ice into 1.5 ml homogeni-
sation buffer (250 mM Sucrose, 10 mM Hepes, 2 mM
EDTA). After centrifugation (5 min at 2000 rpm), cell pel-
lets were homogenised in a homogenisation buffer con-
taining 20 μg/ml each of chymostatin, leupeptin, antipain
and pepstatin A (Sigma) through a 26 G needle and cen-
trifuged for 5 min at 3000 rpm. The resulting supernatant
was subjected to extraction for 30 min at 4°C in 1% Triton
X-100. The extracts were adjusted to 40% OptiPrep (Axis-
Shield, Oslo, Norway) and overlaid in a TLS 55 centrifu-
gation tube with 30% OptiPrep/TNE and TNE (25 mM
Tris-HCl, pH 7.4, 150 mM NaCl, 2 mM EDTA old proto-
col/25 mM Tris-HCl, pH 10.8, 150 mM NaCl, 5 mM
EDTA). The gradients were centrifuged at 400000 g in a
Beckman SW41 rotor for 20 h at 4°C. Fractions were
obtained and used for Western blotting as described [23].
Monoclonal antibodies against TNF-α receptor 1 (TNF-α-
R1) were from Sigma and TNF-α receptor 2 (TNF-α-R2)
from Alexis Biochemical (Lörrach, Germany); mono-
clonal antibodies against the Src-like kinase Yes were sup-
plied from Transduction Laboratories (Lexington, K Y);
and against Flotillin-1 came from BD Bioscience (Heidel-
berg, Germany).
Statistical analysis
All values are reported as mean and standard deviation
(SD) or standard error of the mean (SEM). For homogene-
ity of variance, ANOVA was applied. Significance levels
between single groups (medium, +TNF-α, +TNF-α +phos-
pholipid) were analysed using Tukey's post-hoc test. Prob-
ability values of p < 0.05 were set as a threshold for
statistical significance.BMC Gastroenterology 2009, 9:53 http://www.biomedcentral.com/1471-230X/9/53
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Results
Different species of PC inhibit TNF-α-induced NF-κB 
activation in Caco-2 cells
Within our study, we tested the effect of several PC species
(LPC 16:0, PC 18:2/18:2, PC 16:0/16:0, and PC 16:0/
18:2) on the TNF-α-induced p65 promoter binding. First,
Caco-2 cells were co-treated with TNF-α (10 ng) and PC.
The promoter binding of p65 was detected by transient
expression of a NF-κB luciferase reporter system and com-
pared to the state of untreated cells. All PC species tested
significantly inhibited the activation of NF-κB. As more
unsaturated fatty acids the PC molecule had as more effec-
tive was the compound. The strongest effects were seen
with LPC 16:0 (1-palmitoyl-glycero-3-PC) followed by PC
18:2/18:2 (1, 2-dilinoleoyl-glycero-3-PC). PC 16:0/16:0
was least effective. The effect was dose dependent for all
PC species as previously shown for PC 18:2/18:2 [11] (see
Additional file 1).
Whenever a co-treatment experiment is performed, there
is a risk that the applied substances could interfere with
each other within the medium. Therefore, we also tested
whether the pre-incubation of our cells with PC (pre-treat-
ment) is effective. Cells were first incubated with the
respective lipid, washed and subsequently stimulated
with TNF-α. Interestingly, pre-treatment resulted in a
time-dependent inhibition of the NF-κB activation.
Within the first 30 min, NF-κB activation decreased with
increasing time of pre-treatment. Pre-treatment for longer
time periods did not show any additional effect (p > 0.05)
(Figure 1). [3H]-PC uptake kinetics revealed that the inter-
nalisation of PC was almost linear within the first 5 min
and thereafter reached a plateau that possible explains
why no additional effect on NF-kB activation was seen
with longer pre-treatment times (see Additional file
2[24]).
Expression of pro-inflammatory genes is attenuated by PC
In previous publications, we have already shown that PC
has an effect on pro-inflammatory gene transcription
downstream of NF-κB [11]. In order to evaluate this effect
in more detail, we analysed longer time periods and an
extended set of genes. Caco-2 cells were stimulated with
10 ng/mL TNF-α for various times (30 to 240 min). There-
after, mRNA was isolated to analyse the transcriptional
levels by quantitative RT-PCR. Using this method, a signif-
icant up-regulation of IL-8, ICAM-1, IP-10, MCP-1, TNF-α
and MMP-1 could be detected compared to the mRNA
level of untreated cells (control) (p < 0.05) (see Addi-
tional file 3). Other genes (Cox-2, IL-10, IL-18, 4-1BB,
ENA-78, TGFβ1) failed to be up-regulated by TNF-α (p >
0.05). After co-treatment of cells with PC 16:0/16:0 (1, 2-
dipalmitoyl-glycero-3-PC) (+TNF-α +PC), the TNF-α
effect was significantly reduced (p < 0.05). Similar effects
were found for the treatment with LPC 16:0 (1-palmitoyl-
glycero-3-PC). For evaluation of substrate specificity, we
also tested the effect of PE 16:1/16:1 (1,2-dioleyl-glycerol-
3-phosphatidylethanolamine (PE)). Co-treatment of cells
with TNF-α and PE did not show any significant effect on
the transcriptional level of ICAM-1, IP-10, MCP-1, TNF-α,
MMP-1, Cox-2, IL-10, IL-18, 4-1BB, ENA-78 or TGFβ1
compared to TNF-α alone (p > 0.05).
Interestingly, some genes were up-regulated faster than
others. This led us to classify the genes into two groups: 1)
early up-regulated genes (IL-8, TNF-α), where a significant
increase in transcript levels could be detected within 30
min; and 2) late up-regulated genes (ICAM-1, MCP-1,
IP10, MMP-1) which responded later. PC pre-treatment
reduced the transcriptional levels of both groups of genes
significantly. The effect lasted for up to 120 min. Analys-
ing later time points (240 min) did not show a significant
difference anymore. The only exception was MMP-1,
where a significant difference could also be detected after
240 min (see Additional file 3). This observation may be
due to metabolic effects.
The effect of PC on the expression levels of selected genes 
is comparable to the effect of the NF-κB inhibitor SN 50
It is known that the cytokine-induced expression of IL-8,
MCP-1, COX-2 and other genes involved in inflammation
is highly dependent on the transcription factor NF-κB [25-
27]. An inhibitory effect of PC on the activation of the
MAPkinases ERK and p38 have been previously described
[11]. If we extend this by hypothesizing that PC inhibits
TNF-α induced NF-κB activation and the subsequent pro-
inflammatory gene transcription upstream of NF-κB, we
could expect similar effects on gene transcription by
inhibiting NF-κB in a direct way. Therefore we carried out
experiments with the specific NF-κB-inhibitor SN 50. Pre-
incubation of Caco-2 cells with SN 50 for 30 min before
stimulation with TNF-α (10 ng/mL) resulted in a signifi-
cantly reduced up-regulation of IL-8, ICAM-1, MCP-1 and
IP-10. The inhibitory effects with SN 50 were as strong as
the effects seen after pre-incubation with 200 μmol of
either PC 16:0/16:0 (1, 2-dipalmitoyl-glycero-3-PC) (see
Additional file 4) or LPC 16:0 (1-palmitoyl-glycero-3-PC)
(data not shown). Therefore, the inhibitory effect of PC
seems to be regulated within the TNF-α/NF-κB-pathway
probably upstream of NF-κB.
PC has no effect on the binding of TNF-α to its receptors
To exclude the possibility that PC might be acting by
inhibiting the interaction of TNF-α to its receptors, we
performed FACS analyses using biotin labeled TNF-α and
avidin-FITC. The interaction of TNF-α with its receptor
was readily and reproducibly observed in cells treated
with either TNF-α-biotin alone or with cells pre-incubated
for 1 h prior to the addition of TNF-α-biotin with 200
μmol of either PC 16:0/16:0 (1, 2-dipalmitoyl-glycero-3-BMC Gastroenterology 2009, 9:53 http://www.biomedcentral.com/1471-230X/9/53
Page 5 of 11
(page number not for citation purposes)
PC) or PC 18:2/18:2 (1, 2-dilinoleoyl-glycero-3-PC).
None of the tested PC species affected the interaction of
TNF-α to its receptors or changed the density of TNF-α
receptors at the cell surface (see Additional file 5).
PC and LPC changes compartmentation of TNF-α-R1 and 
TNF-α-R2 to lipid rafts at the plasma membrane
We have previously shown that PC can inhibit the TNF-α-
induced activation of the MAPkinases ERK and p38 [11].
If the effect of PC on TNF-α-induced gene transcription
were indeed to take place upstream of NF-κB activation, it
would possibly happen because of the lipophilic character
of the substance within or at the plasma membrane. It has
been previously shown that TNF-α receptors reside at the
plasma membrane at least partially in lipid rafts and it has
been suggested that compartmentation influences the sig-
nalling response [28]. As shown in Figure 2, PC does not
change the concentration of TNF-α receptors at the cell
surface. Therefore, we hypothesized that PC might not
change the overall concentration but possibly the com-
partmentation of TNF-α receptors within the plasma
membrane. DRMs were prepared in order to evaluate this
hypothesis. Caco-2 cells were transfected with TNF-α-R1
and TNF-α-R2 and then extracted with Triton X-100 and
subjected to OptiPrep step gradient centrifugation. TNF-
α-R1 and TNF-α-R2 were found in two pools in cellular
membranes, one within the DRMs and one outside of the
DRMs. PC or LPC treatment shifted both receptors
towards an increased DRM association (Figure 2). PC and
LPC induced also an increased DRM association for the
raft marker proteins Yes and Flotillin-1 (data not shown)
that served as controls.
PC inhibits the TNF-α-induced up-regulation of selected 
genes from the apical and basolateral sides of fully 
polarised Caco-2 cells
Based on the results with non-polarised cells, we also car-
ried out analyses with fully polarised, filter grown Caco-2
cells. To establish this system, we tried out several condi-
tions to stimulate the cells. It has been previously
described that in fully polarised Caco-2 cells, the TNF-α-
receptor is localised at the basolateral side and therefore
not accessible for TNF-α applied to the apical surface
[29,30]. We could confirm this finding by analysing the
transcriptional level of selected genes after stimulating the
cells with TNF-α from the apical and basolateral sides. An
up-regulation could only be detected after stimulation
from the basolateral side (Figure 3). Interestingly, PC and
Pre-incubation with a 200 μM solution of PC resulted in a time-dependent inhibition of TNF-α induced NF-κB activation Figure 1
Pre-incubation with a 200 μM solution of PC resulted in a time-dependent inhibition of TNF-α induced NF-κB 
activation. NF-κB-activation was analysed via the transient expression of a NF-κB luciferase reporter system in Caco-2 cells. 
Cells were pre-treated with PC 16:0/16:0 (1, 2-dipalmitoyl-glycero-3-PC) for 5–120 min, washed and exposed for 4 h to 10 ng/
ml TNF-α. The value was arbitrarily set to 100% in cells treated with TNF-α but not with lipid pre-treatment. Results pre-
sented here are representative for three others carried out independently. Data are expressed as mean and SD (n = 3). Aster-
isks assign statistically different values from Tukey's post hoc test compared to +TNF-α (*p < 0.05; **p < 0.01; ***p < 0.001).BMC Gastroenterology 2009, 9:53 http://www.biomedcentral.com/1471-230X/9/53
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LPC inhibited TNF-α-induced gene transcription from
both domains (Figure 4).
Discussion
The data we have presented here further strengthens the
evidence that the application of exogenous PC has anti-
inflammatory effects. Firstly, we could confirm that differ-
ent PC species can inhibit TNF-α-induced NF-κB activa-
tion. LPC functioned in the same way, whereas PE was not
effective. The effect of PC was not merely transient but
instead persisted for at least for 2 h. Consistent with pre-
vious results [11], we could demonstrate that the effect is
dose dependent. Interestingly, PC 16:0/16:0 was less
effective than species with unsaturated fatty acid side
chains. As human mucus is made up of more than 90%
PC species with one unsaturated fatty acid side chain (PC
16:0/18:1; PC 16:0/18:2; PC 18:0/18:1 and PC 18:0/18:2)
[5], it is intriguing to speculate that this might represent
an optimal mixture for controlling the inflammatory
response. The hypothesis deduced from this is that mucus
PC might be a source for membrane PC in enterocytes and
thus influence membrane-dependent signalling of the
mucosa cells.
Clinical and animal as well as in vitro data further support
the anti-inflammatory effect of PC. We and others have
previously shown that PC inhibits actin polymerisation
on isolated phagosomes as well as in macrophages and
Caco-2 cells [11,12]. In the latter model, it also inhibits
activation of the MAPkinases ERK and p38, which are
upstream of NF-κB [11]. Many animal studies support
that PC is protective against pro-inflammatory condi-
tions. With respect to this, it as been shown that it pre-
vents mucosal injury induced by acids, NSAIDs or bile
acids [9,31-39]. Parenteral administration of PC or LPC
has been demonstrated to increase survival and improve
inflammation in animal models of acute septic shock and
endotoxemia [40-42]. Interestingly, there is a sudden
overproduction of TNF-α in acute septic shock which trig-
gers hypotension, circulatory collapse, and the wide-
spread inflammation seen in this clinical condition [43].
Various species of LPC seem to protect against such a con-
dition [42]. TNF-α is also thought to be an important
agent in the colonic inflammation of patients with ulcer-
ative colitis (UC). There is an increased density of TNF-α
immunoreactive cells in the mucosa of UC patients with
actual inflammation and there is an increased concentra-
tion of TNF-α in faeces, mucosa biopsies and serum of
actively ill patients [44-46]. Most importantly, clinical
studies have revealed that an anti-TNF-α strategy can be
successful in treating those patients; therefore, this strat-
egy is now integrated in daily clinical practice [47]. Two
clinical studies on patients with ulcerative colitis have
been performed which show a therapeutic benefit by add-
ing PC in the form of slow release preparations [6,7]. In
these studies, PC was applied in the form of soy lecithin
with a considerable amount of PE. PE can be metabolised
to PC via methylation and therefore serves as an addi-
tional source for PC within the cell. PE is also a known
source for the endocannabinoid system, which influences
inflammatory reactions as well [48]. However, our data
show that exogenous PE has no significant effect on TNF-
α-induced activation. This probably means that it is not
the effective component of the preparation used in the
clinical trials.
TNF-α exerts its functions through two distinct receptors,
TNF-α-R1 (CD120a) and TNF-α-R2 (CD120b). After
binding TNF-α, TNF-α-R1 recruits a death domain (DD)-
containing adaptor molecule, namely the TNF-α-R1-asso-
ciated death domain protein (TRADD). TRADD serves as
a platform for recruiting additional mediators [49]. It
binds the DD-containing Ser/Thr kinase receptor-interact-
ing protein (RIP) and TNF-receptor-associated factor 2
(TRAF2). This TRADD-RIP-TRAF2 complex initiates the
pathway leading to NF-kB activation [50-52]. How might
exogenous PC function in this regulation?
1. It could be speculated that PC or LPC inhibits the asso-
ciation of TNF-α to its receptor. To exclude such an effect,
we performed experiments in which the cells were treated
with PC before TNF-α stimulation and quantified the
binding of TNF-α to its receptor by FACS. FACS analysis
could detect no quantitative differences between PC or
LPC treated and non-treated cells. This makes a decreased
receptor binding unlikely.
This figure represents the effect of both LPC and PC on the  association of TNF-α-R1 and TNF-α-R2 to DRMs Figure 2
This figure represents the effect of both LPC and PC 
on the association of TNF-α-R1 and TNF-α-R2 to 
DRMs. COS cells were lysed in 1% Triton X-100 at 4°C 20 h 
after transient transfection of TNF-α-R1 and TNF-α-R2. 
After floatation in an OptiPrep step-gradient, TNF-α-R1 and 
TNF-α-R2 were found in two pools, in DRMs (lane 7–8) and 
in soluble membranes (lane 1–4). Pre-treatment with 200 
μmol LPC or PC resulted in an increased DRM association.BMC Gastroenterology 2009, 9:53 http://www.biomedcentral.com/1471-230X/9/53
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2. It has been previously suggested that TNF-α receptors,
upon substrate binding, might be endocytosed and that
the signalling response occurs in endosomes, as demon-
strated in other receptors such as the β2-adrenergic recep-
tor, the endothelin receptor and many other G-coupled
protein receptors [53-56]. Thus it has been speculated that
the integration of PC into cellular membranes might
affect endocytosis and consequently signalling. However,
we could show by FACS analysis that the surface expres-
sion of TNF-α receptors was unchanged after PC treat-
ment. This makes an influence of PC on endocytosis also
unlikely.
3. A third scenario seems more likely. Mammalian mem-
branes are lipid bilayers consisting of 300–400 different
lipid species that are ordered in vertical and lateral dimen-
sions. This order is maintained with the help of a highly
regulated concert of enzymes. Adding exogenous lipids
would lead to a change in the lipid assembly of the mem-
brane and therefore would influence membrane-depend-
ent processes. We have previously speculated that PC
might be present in a freely mobile form and a pool that
is attached to proteins [11]. Proteins that bind selectively
to PC have been described (e.g., START, C1 or C2 domain
structures), of which a large number are involved in sig-
nalling [57,58]. Adding PC might shift the balance
between the free and the bound fractions. Normally in
cells the bulk of PC is in the outer leaflet of the mem-
brane. It is therefore also possible that addition of PC
might induce a higher concentration of PC on the inner
leaflet. There it could interfere with selected signalling
proteins such as MAP kinases or others involved in NF-κB
activation. However, it has to be mentioned that the role
of NF-κB is more complex in regulating the answer of the
intestinal epithelium to luminal agents. NF-κB has been
shown to regulate protective factors as well, including
inducible beta defensins [59]. Epithelial-cell-specific inhi-
bition of NF-kB through conditional ablation of NEMO
(IKKgamma) led to an increased apoptosis of colonocytes,
impaired expression of antimicrobial peptides and trans-
location of bacteria into the mucosa [60]. NF-κB therefore
seems to be a regulator for the intestinal immune homoe-
ostasis and the tuning of its activity by many mechanisms
appears crucial in preventing inflammation [61]. The pool
of membrane PC could be a part of this regulation.
4. Not only proteins but also membrane lipid compart-
ments are necessary for TNF-α signalling to occur. It has
been previously shown that TNF-α binding recruits TNF-
α-R1 to lipid rafts [28]. Rafts are small platforms com-
posed of sphingolipids and cholesterol in the outer exo-
plasmic leaflet and connected to phospholipids and
cholesterol in the inner cytoplasmic leaflet of the lipid
bilayer [62]. These assemblies are fluid but more ordered
and tightly packed than the surrounding bilayer. The dif-
ference in packing is due to the saturation of the hydrocar-
bon chains in raft sphingolipids and phospholipids as
compared with the unsaturated state of fatty acids of
phospholipids in the surrounding bilayer [62]. Therefore
it is possible that a change in the phospholipid concentra-
tion within the membrane has an impact on the lipid raft
integrity. Discrepancies in the localisation of TNF-α-R1 to
lipid rafts exist. Although in U937 and NIH-3T3 cells TNF-
α-Rs were found mainly in lipid rafts and were shifted to
detergent soluble parts upon TNF-α stimulation [63],
TNF-α increased their lipid raft association in HeLa [64]
and HT1080 fibrosarcoma cells [65]. Conflicting data also
exist concerning a compartmentalised NF-kB activation.
Whereas some authors claim that NF-kB activation by
TNF-α occurs in lipid raft domains [28] other publications
suggest a lipid-raft-independent activation [63]. However,
our data showed that upon exposure of Caco-2 cells with
PC or LPC, the lipid raft associations of both TNF-α-R1
and TNF-α-R2 are increased and both lipids were inhibi-
tory in our setting. Therefore, we assume that TNF-α-
induced NF-kB activation occurs outside lipid rafts.
To get closer to the scenario in the mucosa, polarised
Caco-2 cells were analysed as well. Although polarised
cells could only be stimulated by basolateral exposure to
TNF-α, an inhibitory effect of PC could be observed from
both the apical and basolateral sides. The cause of this
This figure shows the effect of TNF-α from the apical and  basal sides on gene transcription Figure 3
This figure shows the effect of TNF-α from the apical 
and basal sides on gene transcription. Caco-2 cells were 
grown in a 6-transwell system and stimulated with TNF-α 
(50 ng/mL) to induce an up-regulation of several selected 
genes involved in inflammation. Only basolateral stimulation 
with TNF-α (TNF-α bl) resulted in a significant up-regulation 
while apical stimulation with TNF-α (TNF-α ap) did not 
show any significant effect (p > 0.05). Data are expressed as 
mean and SD of n = 3 experiments. Asterisks assign statisti-
cally different values comparing apical and basolateral stimu-
lation (*p < 0.05; **p < 0.01; ***p < 0.001).BMC Gastroenterology 2009, 9:53 http://www.biomedcentral.com/1471-230X/9/53
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phenomenon requires further investigation; however, a
possible explanation may be that TNF-α signalling occurs
after internalisation and that apical and basolateral vesi-
cles mix with each other in the endosomal compartments
[56]. Another possible explanation is that PC is integrated
and rapidly exchanged between the apical and basolateral
domains via the inner layer of the plasma membrane [66].
Conclusion
In summary, our results further support the idea that
exogenous PC and LPC have anti-inflammatory proper-
ties. Our findings suggest that PC (LPC) inhibits the sig-
nalling responses via NF-κB possibly due to changes in the
plasma membrane. This is a potential mechanism
explaining how PC can influence the course of ulcerative
colitis and provides the molecular foundation for the ben-
efit seen in our clinical studies.
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PC inhibits pro-inflammatory gene transcription from both the apical and basolateral sides of polarised Caco-2 cells Figure 4
PC inhibits pro-inflammatory gene transcription from both the apical and basolateral sides of polarised Caco-
2 cells. Polarised Caco-2 cells were grown in a 12-transwell system and stimulated with TNF-α (50 ng/mL) from the basola-
teral side to induce an up-regulation of several genes (IL-8, IP-10, and MMP-1) involved in inflammation (TNF-α). Both basola-
teral (+TNF-α +PC bl) and apical (+TNF-α +PC ap) treatments with 200 μmol of PC 16:0/16:0 (1, 2-dipalmitoyl-glycero-3-PC) 
resulted in a significant reduction in the TNF-α-induced up-regulation. Asterisks assign statistically different values from 
Tukey's post hoc test of TNF-α to all other values at each time point (*p < 0.05; **p < 0.01; ***p < 0.001); At no time point 
could a significant difference of +TNF-α +PC ap and +TNF-α +PC bl be detected; crosses indicate significant differences of 
control compared to both +TNF-α and +TNFα +PC at each time point (+ p < 0.05; ++ p < 0.01; +++ p < 0.001).BMC Gastroenterology 2009, 9:53 http://www.biomedcentral.com/1471-230X/9/53
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Additional file 1
Co-treatment of Caco-2 cells with TNF-α and phospholipids. Cells 
were grown in 3.5 cm dishes and the effects of different PC species on the 
inhibition of TNF-α-induced NF-κB-activation were analysed via the 
transient expression of a NF-κB-luciferase reporter system. (A) Cells were 
co-treated with 10 ng TNF-α and 200 μmol of the respective lipid. Luci-
ferase activity was analysed 4 h after stimulation. Interestingly, PC 18:2/
18:2 (1, 2-dilinoleoyl-glycero-3-PC), a PC species with two unsaturated 
side chains, was the most effective one compared to both PC 16:0/16:0 
(1, 2-dipalmitoyl-glycero-3-PC) and PC 16:0/18:2 (1-palmitoyl-2-linole-
oyl-glycero-3-PC) (p < 0.05). (B) Cells were co-treated with 10 ng/ml 
TNF-α and the indicated amounts of PC 16:0/16:0. PC inhibited NF-κB 
activation in a dose-dependent manner. The strongest effect was seen with 
200 μmol PC which was significantly different from all other PC concen-
trations tested. The value was arbitrarily set to 100% in cells treated with 
TNF-α but not with phospholipids. Results presented here are representa-
tive for three others carried out independently. Data are shown as mean 
and SD (n = 3). Asterisks assign statistically different values from Tukey's 
post hoc test compared to control (*p < 0.05; **p < 0.01; ***p < 0.001); 
crosses indicate significant differences from +TNF-α after treatment with 
different phospholipids or phospholipid concentrations (+ p < 0.05; ++ p 
< 0.01; +++ p < 0.001).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
230X-9-53-S1.tiff]
Additional file 2
Uptake of [3H]-PC 16:0/16:0 into Caco-2 cells. To investigate whether 
the time-dependent inhibition of NF-κB activation correlates to the 
amount of PC taken up into the cells, we analysed the uptake of [3H]-PC 
16:0/16:0. Methods: Caco-2 cells were grown to 80% confluence in 5 cm2 
dishes and incubated for various times with different concentrations of 1-
, 2-dipalmitoyl-3-phosphatidyl-[N-methyl-[3H]-choline ([3H]-PC, 81 
Ci/mM) and 1-, 2-dipalmitoyl-glycero-3-phosphocholine (PC 16:0/16:0) 
at a ratio of 1:250. After washing, cells were incubated with NaOH (1 
M) for 10 min. Both the cell lysates and the supernatants were analysed 
with counting solution in a scintillation counter (Beckman Coulter LS 
6500) as done previously [11,24]. [3H]-methyl-choline]-L-dipalmitoyl-
phosphatidylcholine ([3H]-PC) (50 Ci/mmol) was purchased from New 
England Nulcear, (Boston, MA, USA). Results: (A) The uptake reaches 
a plateau with increasing time. (B) Within the first 5 min of incubation 
with PC, the uptake was almost linear. An additional PC uptake was not 
detectable after 1 h. This uptake kinetic probably indicates that the inhib-
itory effect of exogenous PC correlates to the amount of PC incorporated 
into the cells. The plateau after 1 h likely explains why no additional effect 
on NF-κB activation was seen with longer pre-treatment times (Figure 1). 
Data are expressed as mean and SD of n = 5 experiments.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
230X-9-53-S2.tiff]
Additional file 3
Effect of PC 16:0/16:0 on up-regulation of selected pro-inflammatory 
genes after TNF-α stimulation. Sub-confluent Caco-2 cells were stimu-
lated with 10 ng/ml TNF-α to induce an up-regulation of MMP-1, IL-8, 
ICAM-1, MCP-1 and IP-10, which are known to be pro-inflammatory. 
(A) Co-treatment with 200 μmol of PC 16:0/16:0 (1, 2-dipalmitoyl-glyc-
ero-3-PC) resulted in a significant inhibition of the TNF-α-induced up-
regulation. Up-regulation of selected genes after TNF-α stimulation might 
be classified into two groups: 1) early up-regulated genes (such as IL-8) 
and 2) late genes (ICAM-1, IP-10, MCP-1). The experiment depicted is 
representative of three others with the same results. Data are expressed as 
mean and SEM (n = 3). Asterisks assign statistically different values from 
Tukey's post hoc test (*p < 0.05; **p < 0.01; ***p < 0.001) comparing 
+TNF-α and +TNF-α +PC at each time point; crosses indicate significant 
differences of control compared to both +TNF-α and +TNF-α +PC at each 
time point (+ p < 0.05; ++ p < 0.01; +++ p < 0.001).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
230X-9-53-S3.tiff]
Additional file 4
Effect of SN 50 and PC on TNF-α-induced gene activation. Sub-con-
fluent Caco-2 cells were stimulated with TNF-α (10 ng/mL) to induce an 
up-regulation of several selected genes. Pre-treatment with the NF-κB 
inhibitor SN 50 (50 mg/mL) for 30 min resulted in a significant reduc-
tion of the TNF-α-induced up-regulation. This reduction was similar to 
that found in cells treated with PC, possibly indicating that both treat-
ments influence the same pathway. Data are expressed as mean and SEM 
(n = 3). Asterisks assign statistically different values from Tukey's post hoc 
test of +TNF-α to all other values at each time point (*p < 0.05; **p < 
0.01; ***p < 0.001); At no time point could a significant difference of 
+TNF-α +PC and +TNF-α +SN 50 be detected with the exception ICAM-
1 at 120 min. Crosses indicate significant differences of control compared 
to +TNF-α, TNF-α +SN 50 and +TNF-α +PC at each time point (+ p < 
0.05; ++ p < 0.01; +++ p < 0.001).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
230X-9-53-S4.tiff]
Additional file 5
Neither PC 16:0/16:0 nor PC 18:2/18:2 showed any effect on the 
binding of TNF-α to its cell surface receptors. Vero cells were taken for 
FACS analyses because of their regular cell shape. They were either left 
untreated or were pre-treated for 1 h prior to the addition of TNF-α-biotin 
with a 200 μM preparation of PC 16:0/16:0 (1, 2-dipalmitoyl-glycero-3-
PC) or PC 18:2/18:2 (1, 2-dilinoleoyl-glycero-3-PC). The PC-treated 
(TNF-α-biotin + PC 16:0/16:0 or TNF-α-biotin + PC 18:2/18:2) and 
untreated (TNF-α-biotin) cells were then collected for staining with bioti-
nylated TNF-α and avidin-FITC. Soybean trypsin inhibitor that had been 
biotinylated in the same degree was used as a negative control. Neutral-
ized TNF-α biotin with anti-TNF-α blocking antibody was used as a spe-
cificity control. Receptor binding activity was determined by flow 
cytometric analysis with a 488 nm wavelength laser excitation. Results 
shown here were representative for three other experiments carried out 
independently.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
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